Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for.

Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market

January 16, 2024

Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

January 16, 2024

Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?

A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics

January 10, 2024

Via Benzinga

January 09, 2024

Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the...

Via Benzinga

Topics Economy

Sarepta Therapeutics Inc. (NASDAQ: SRPT) Making Surprising Moves in Tuesday Session

January 09, 2024

Via Investor Brand Network

Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year

January 09, 2024

Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product

Via Benzinga

Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match

January 09, 2024

Bumble stock is rising on Tuesday as BMBL investors learn of a $1 billion investment in rival dating services company Match.

Sarepta Therapeutics stock is rising higher on Tuesday as SRPT investors react to positive comments from company CEO Douglas Ingram.

Why Is Sarepta Therapeutics (SRPT) Stock Up Today?

January 09, 2024

Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday

January 09, 2024

U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.

Via Benzinga

Topics Stocks

2 Growth Stocks That Could Make You Richer in 2024 and Beyond

January 09, 2024

Last year wasn't great for either stock, but that's no reason to ignore them.

Can this struggling stock turn its fortunes around?

The Latest Analyst Ratings for Sarepta Therapeutics

December 12, 2023

Via Benzinga

Could Sarepta Therapeutics Stock Help You Become a Millionaire?

December 09, 2023

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue

Analyst Ratings for Sarepta Therapeutics

November 21, 2023

Via Benzinga

January 08, 2024

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024

January 07, 2024

Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...

Via Talk Markets

Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024

January 04, 2024

Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...

Via Benzinga

Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 29, 2023

Mastering this stock requires appreciating a few scientific nuances.

3 Things About Sarepta Therapeutics Every Smart Investor Knows

December 28, 2023

Both develop medicines for rare diseases, and each aims to conquer a niche market.

10 Health Care Stocks Whale Activity In Today's Session

December 27, 2023

Via Benzinga

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?

December 22, 2023

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status

December 22, 2023

Many investors are bailing out, but that might be a mistake.

1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond

December 17, 2023

These strong stocks are still available at a great price. That may not be the case a whole lot longer.

My Take: 4 Strong Growth Stocks to Buy This Week

December 08, 2023

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 30, 2023

ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

November 18, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

3 Monster Stocks in the Making

November 18, 2023

These stocks could grow much larger over the next few years.

These stocks to buy are the ones to scoop up soon for long-term growth as these companies have stable growth catalysts in the coming years.

3 Stocks You’ll Regret Not Buying Soon: November 2023

November 16, 2023